Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cholangiocarcinoma

NCT02482454 · tracked via the Priya Life Science China tracker

Sponsor

The First People's Hospital of Changzhou

Phase

Phase 2/3

Started

2012-07

Last updated

2017-08-01

Condition(s) studied

Cholangiocarcinoma

Investigational drug(s) / intervention(s)

Radiofrequency ablationCytokine-induced killer cells

Radiofrequency ablation: Radiofrequency ablation is performed percutaneously under CT/US guidance

Cytokine-induced killer cells: The patients received autologous cytokine-induced killer cells transfusion one week after RFA treatment.

Study summary

The purpose of this study is to determine whether combining of radiofrequency ablation (RFA) and cytokine-induced killer cells (CIK) transfusion can prolong survival of patients with cholangiocarcinoma.

Eligibility

Sex

ALL

Min age

30 Years

Max age

80 Years

Healthy volunteers

Inclusion Criteria: * Patients with histologically confirmed cholangiocarcinoma * Primary lesions (cholangiocarcinoma) are not resected * Serum bilirubin level of 2.0 mg/dl or less. * Performance status of 0 or 1. * Expected survival of 1 year or more. * Informed consent from the patient. Exclusion Criteria: * With extrahepatic metastases * With other neoplastic disease that is measurable or being treated other than cholangiocarcinoma.

Primary outcome measure(s)

Recurrence-free survival — 1 year
Recurrence-free survival (RFS) was defined as the time from the date of RFA to the date of recurrence or the date of the last follow-up.

Trial sites (1)

Facility	City	Region	Status
The First People's Hospital of Changzhou	Changzhou	Jiangsu

More The First People's Hospital of Changzhou trials in China

Safety and Efficacy of Combined B Cell Depleting theRapy And Daratumumab In Autoimmune Encephalitis Recruiting

Regorafenib and Sintilimab in Combination with Electroacupuncture in MSS CRC Recruiting

Clinical Trial of Safety and Efficacy of Intracranial Laser Balloon Dilation Catheter in Patients With Symptomatic Intracranial Atherosclerotic Stenosis: A Prospective, Multi-center, Randomized Comparison Enrolling by invitation

Human Umbilical Cord Mesenchymal Stem Cell Infusion for Type 2 Diabetic Nephropathy Starting soon

Other trials for the same condition

Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxans-resistant Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Gastric Cancer, Esophageal Carcinoma, or Breast Cancer Recruiting

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) Active, not recruiting

Dual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer Recruiting

Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer Recruiting

Cadonilimab Combined With Liposomal Irinotecan Plus Leucovorin and Fluorouracil for Advanced Cholangiocarcinoma Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT02482454 on ClinicalTrials.gov ↗ ← All trials in China